Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeSubmitted by Jeffrey Neal Johnson. Publication Date: 12/31/2025. 
In Brief - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market of 2025 will be remembered for its extremes. While investors poured billions into technology giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left behind. Nowhere is this more evident than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finishes the year as one of the most unloved assets in the S&P 500. On the surface, the pessimism looks warranted: revenue from COVID-19 products dropped faster than expected, several high-profile pipeline candidates failed, and activist investors waged a public campaign against management. The #1 memecoin for the new year
With the market oversold and a potential new year rally just around the corner, this could be one of the most explosive opportunities of the new year. Get the #1 memecoin for January 2026 here. But the worst of the storm may be behind Pfizer. With activist Starboard Value exiting in November and management resetting guidance to more realistic levels, much of the bad news is already priced in. That suggests Pfizer’s stock price has likely found a floor. Entering 2026, the company presents a rare situation: a blue-chip name trading at distressed levels, paying an attractive dividend while it quietly rebuilds its pipeline. The Mathematical Case: Why the Price Is Wrong For value investors, the case for Pfizer is straightforward: the market is pricing the company as if its earnings will permanently shrink, creating a wide gap between the share price and the company’s cash-generating capacity. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio (P/E) of roughly 8.6x. By comparison, the average pharmaceutical company trades at 15x–20x earnings, and high-growth peers such as Eli Lilly (NYSE: LLY) command materially higher multiples. A P/E of 8.6x implies little to no growth priced in, which sets a low bar. Pfizer does not need a miracle to see its stock recover; it simply needs to demonstrate stability. Any positive earnings surprise or clearer growth trajectory could prompt a multiple expansion as the stock realigns with industry averages. The Dividend Shield While investors wait for that repricing, they are paid to hold the stock. - Annual payout: $1.72 per share.
- Current yield: ~6.9%.
That yield is roughly four times the S&P 500 average and provides a margin of safety. Even if the share price remains unchanged through 2026, a near-7% dividend alone delivers returns that beat most savings accounts and government bonds. Management is supporting the dividend with a $4 billion cost-savings program. By trimming administrative overhead and optimizing manufacturing, they are protecting the cash flow that funds those quarterly payments. The New Foundation: Oncology Takes the Lead A major criticism of Pfizer is that the decline of its COVID business left a growth gap. Management has responded by pivoting aggressively toward oncology. Guided-missile technology The centerpiece of Pfizer’s 2023 acquisition of Seagen is leadership in Antibody-Drug Conjugates (ADCs). Where traditional chemotherapy is a broad blast, ADCs act like guided missiles—targeting cancer cells and delivering a toxic payload while sparing healthy tissue. This approach is already contributing revenue. The Seagen portfolio brought in about $3.4 billion in 2024 and previously delivered roughly $2.75 billion in the first three quarters after the deal, driven in part by strong Padcev sales for bladder cancer. Navigating the bumps The path hasn’t been perfectly smooth. In December 2025, Pfizer reported a safety signal around Hympavzi, a hemophilia treatment, including a patient death in a trial extension. That news rattled investors, but it does not negate the larger thesis. The oncology pipeline remains deep—more than 60 programs are in development—and Pfizer recently licensed a promising bispecific antibody from 3SBio, reinforcing its efforts to reload the pipeline. Catching Up: The Strategy for Weight Loss After an early setback with its oral candidate Danuglipron, Pfizer refused to concede the lucrative weight-loss market. In late 2025 the company pivoted, buying back into the category through two strategic deals. The injectable strategy (Metsera) In November, Pfizer completed its acquisition of Metsera for about $7 billion. That deal added MET-097i, a next-generation injectable that could be dosed monthly rather than weekly, offering a potentially meaningful convenience advantage for patients. The oral strategy (YaoPharma) At the same time, Pfizer licensed a small-molecule GLP-1 candidate from YaoPharma, acknowledging that many patients prefer oral therapy to injections. Why this matters Pfizer’s current share price effectively assigns zero value to its obesity pipeline. With expectations at rock bottom, any clinical progress for Metsera or the YaoPharma asset represents upside. Pfizer doesn’t need to be first to market; it only needs to capture a portion of what many analysts project to be a $100 billion opportunity. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 as a company in transition but with a reinforced balance sheet. Management has set a revenue floor near $61 billion for 2026, a realistic target that removes some of the uncertainty that haunted the stock. For investors the math is simple. At roughly $25 per share, downside is cushioned by a ~7% yield and historically low valuation. The upside is meaningful: expanding oncology revenues or successful weight-loss candidates could trigger a sharp re-rating. The unloved stocks of one year often become the big winners of the next. With the activist episode behind it and the balance sheet stabilized, Pfizer has moved from a falling knife to a potential core holding for value-oriented portfolios. 2026 may be the year the sleeping giant wakes up.
| 
